{
  "pmcid": "4678179",
  "config": {
    "model": "gpt",
    "strategy": "zero-shot"
  },
  "usage": {
    "input": 19811,
    "output": 617
  },
  "raw_text": "{\"extractions\":[{\"outcome\":\"progression-free-survival (PFS)\",\"intervention\":\"vismodegib plus gemcitabine (GV)\",\"comparator\":\"gemcitabine plus placebo (GP)\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":53,\"comparator_events\":null,\"comparator_group_size\":53,\"intervention_mean\":4.0,\"intervention_standard_deviation\":null,\"comparator_mean\":2.5,\"comparator_standard_deviation\":null},{\"outcome\":\"Median overall survival (OS)\",\"intervention\":\"vismodegib plus gemcitabine (GV)\",\"comparator\":\"gemcitabine plus placebo (GP)\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":53,\"comparator_events\":null,\"comparator_group_size\":53,\"intervention_mean\":6.9,\"intervention_standard_deviation\":null,\"comparator_mean\":6.1,\"comparator_standard_deviation\":null},{\"outcome\":\"Response rates\",\"intervention\":\"vismodegib plus gemcitabine (GV)\",\"comparator\":\"gemcitabine plus placebo (GP)\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":53,\"comparator_events\":null,\"comparator_group_size\":53,\"intervention_mean\":8.0,\"intervention_standard_deviation\":null,\"comparator_mean\":13.0,\"comparator_standard_deviation\":null},{\"outcome\":\"rate of adverse events\",\"intervention\":\"vismodegib plus gemcitabine (GV)\",\"comparator\":\"gemcitabine plus placebo (GP)\",\"outcome_type\":\"binary\",\"intervention_events\":null,\"intervention_group_size\":53,\"comparator_events\":null,\"comparator_group_size\":53,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null}]}",
  "extraction": [
    {
      "outcome": "progression-free-survival (PFS)",
      "intervention": "vismodegib plus gemcitabine (GV)",
      "comparator": "gemcitabine plus placebo (GP)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 53,
      "comparator_events": null,
      "comparator_group_size": 53,
      "intervention_mean": 4.0,
      "intervention_standard_deviation": null,
      "comparator_mean": 2.5,
      "comparator_standard_deviation": null,
      "pmcid": "4678179"
    },
    {
      "outcome": "Median overall survival (OS)",
      "intervention": "vismodegib plus gemcitabine (GV)",
      "comparator": "gemcitabine plus placebo (GP)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 53,
      "comparator_events": null,
      "comparator_group_size": 53,
      "intervention_mean": 6.9,
      "intervention_standard_deviation": null,
      "comparator_mean": 6.1,
      "comparator_standard_deviation": null,
      "pmcid": "4678179"
    },
    {
      "outcome": "Response rates",
      "intervention": "vismodegib plus gemcitabine (GV)",
      "comparator": "gemcitabine plus placebo (GP)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 53,
      "comparator_events": null,
      "comparator_group_size": 53,
      "intervention_mean": 8.0,
      "intervention_standard_deviation": null,
      "comparator_mean": 13.0,
      "comparator_standard_deviation": null,
      "pmcid": "4678179"
    },
    {
      "outcome": "rate of adverse events",
      "intervention": "vismodegib plus gemcitabine (GV)",
      "comparator": "gemcitabine plus placebo (GP)",
      "outcome_type": "binary",
      "intervention_events": null,
      "intervention_group_size": 53,
      "comparator_events": null,
      "comparator_group_size": 53,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "4678179"
    }
  ]
}